Blogs

Jul 18, 2018
Applied Clinical Trials
James Man considers the practical measures firms can take to embed the patient perspective more directly into their R&D planning.
Jul 16, 2018
Applied Clinical Trials
The British government has at last set out its ambitions for cooperation on medicines post-Brexit.
Jul 16, 2018
Applied Clinical Trials
In this interview, Jim Streeter, Global Vice President of Life Sciences Product Strategy at Oracle, will elaborate further on Oracle’s strategy with mHealth in clinical trials.
Jul 16, 2018
Applied Clinical Trials
The question is, how much attention should be paid to historical recruitment figures if the team only reviews the data from one (or two) similar studies?
Jul 12, 2018
Applied Clinical Trials
In this interview, Linda Rawlings, VP of Neurodegenerative Development at Synteract, elaborates on addressing the challenges of neurodegenerative disease clinical trials.
Jul 11, 2018
Applied Clinical Trials
Patients stand to lose the most when sponsors hold too tightly to drugs doomed to fail. This wastes precious time that patients don’t have and squanders valuable resources.
Jul 11, 2018
Applied Clinical Trials
Given the rapid changes in the communication landscape brought about by participative Internet use and social media, it is important to develop a better understanding of these technologies and their impact on health communication.
Jul 05, 2018
Applied Clinical Trials
CBI Conference Producer, Trevor Sosvielle, recently sat down with Matthew Amsden, CEO of ProofPilot to discuss his early work in HIV prevention trials. Amsden shares how these experiences helped shape ProofPilot and its patient-centric clinical trial approach.
Jun 26, 2018
Applied Clinical Trials
The late-June announcement that Ireland is joining the Beneluxa Initiative on Pharmaceutical Policy might suggest renewed vigour for the drive to equip national governments with more clout in their pricing negotiations with international drug firms.
Jun 25, 2018
Applied Clinical Trials
The general assumption that the Policy 0070 data releases were public data releases can be challenged since there is a mechanism to enforce the ToU, and this mechanism will continue to exist after the Agency moves to the Netherlands.
native1_300x100
lorem ipsum